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There is growing attention for chronic diseases in sub-Saharan Africa (SSA) and for bridges between themanagement of HIV/AIDS
and other (noncommunicable) chronic diseases. This becomes more urgent with increasing numbers of people living with both
HIV/AIDS and other chronic conditions. This paper discusses the commonalities between chronic diseases by reviewing models
of care, focusing on the two most dominant ones, diabetes mellitus type 2 (DM2) and HIV/AIDS. We argue that in order to cope
with care for HIV patients and diabetes patients, health systems in SSA need to adopt new strategies taking into account essential
elements of chronic disease care. We developed a “chronic dimension framework,” which analyses the “disease dimension,” the
“health provider dimension,” the patient or “person dimension,” and the “environment dimension” of chronic diseases. Applying
this framework to HIV/AIDS and DM2 shows that it is useful to think about management of both in tandem, comparing care
delivery platforms and self-management strategies. A literature review on care delivery models for diabetes and HIV/AIDS in SSA
revealed potential elements for cross-fertilisation: rapid scale-up approaches through the public health approach by simplification
and decentralisation; community involvement, peer support, and self-management strategies; and strengthening health services.
1. Introduction
There is growing attention for chronic life-long conditions
(CLLCs) in sub-Saharan Africa (SSA) and for the challenge
that these countries face in coping with rising numbers of
patients with such diseases. The strong advocacy for manag-
ing noncommunicable diseases (NCD) appropriately, many
of which are life-long, and the more general focus on health
systems strengthening has catalysed attention for chronic
care [1, 2]. This trend provides an opportunity to move away
from the traditional divide between infectious and noninfec-
tious diseases towards new frameworks for managing disease
in a broader perspective [3, 4]. HIV/AIDS is the most eye-
catching new chronic disease since antiretroviral treatment
(ART) became available at large-scale. Despite this recog-
nition, the models of care and approach for HIV/AIDS
and other infectious diseases and for chronic NCD have
historically grown separately and bringing these together is
no easy task.
Health systems in SSA have developed with their major
objective being the control of acute infections and improving
maternal and child health. The rise of HIV/AIDS brought
about a major change, because for the first time a chronic
health problem received major attention, and called for the
consideration of individual suﬀering and treatment. Delivery
models for large-scale aﬀordable ART led to the “public
health approach”, a simplification and decentralisation of
disease management to primary care level. Though still very
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much facility-based, this approach meant a breakthrough in
thinking about health care delivery. The individual manage-
ment of and care for NCD has been an almost exclusively
High Income Countries’ (HIC) aﬀair until very recently; care
models for diabetes mellitus and other chronic diseases were
developed for these countries and included a strong emphasis
on self-management and patient empowerment. However,
these models are diﬃcult to export to low-resource contexts,
because of their focus on individual care and reliance on
multidisciplinary teams and collaboration between primary
and secondary health care institutions [5].
Estimates are that at present, 285million people are living
with diabetes, 33 million with HIV/AIDS, and 972 million
with hypertension or cardiovascular diseases, withmore than
50% of all of these in Low Income Countries (LIC) [6–9].
Projections for 2030 show that HIV/AIDS, ischemic heart
disease and diabetes mellitus will be the 1st, 3rd, and 11th
cause of DALYs lost [10]. The growing numbers of patients
with Chronic Life-Long Conditions put an immense burden
on health systems and populations, because of increased
needs for health care providers and steadily rising costs of
health care services. Although accurate estimates for chronic-
illness health care expenditure in SSA are diﬃcult to find, fig-
ures from high income countries show the unsustainability of
the traditional professionalised models of chronic care: the
direct health care cost for people with chronic conditions in
the United States accounts for three quarters of the national
health care expenditure while the cost of diabetes care in
European countries is between 2 and 15% of national health
expenditure [5, 11]. Household surveys from low income
countries illustrate that chronic diseases are an important
determinant for households facing catastropic health care
expenditures [12, 13].
Although the literature increasingly identifies the poten-
tial bridges between HIV/AIDS and other chronic condi-
tions’ management, mentioning the need for self-manage-
ment, and primary health care approach, authors do not
elaborate further [14–16]. Little eﬀort has been made to
bring care models for infectious and noninfectious chronic
diseases closer to each other. This separation of caremodels is
increasingly becoming an anachronism with growing num-
bers of people living with both HIV/AIDS and other chronic
conditions related to accelerated aging processes [17].
In this paper, we aim to address this gap, by looking
at commonalities between diseases from the chronicity per-
spective and by reviewing models of care for these diseases.
We focus on diabetes mellitus type 2 (DM2) and HIV/AIDS,
because these, individually and in combination, are becom-
ing increasingly important in SSA. We argue that in order
to cope with care for HIV patients and diabetes patients,
health systems in SSA need to adopt new strategies taking
into account essential elements of chronic disease care.
The paper consists of three parts. In the first part, we
present a framework to describe diﬀerences and parallels
between chronic diseases, looking at four disease-related
dimensions and we apply this framework to compare DM2
and HIV/AIDS. What are the consequences for the organisa-
tion of care?What are potential bridges when it comes to care
organisation/health system organisation for those diseases?
In the second part, we review the present and potentially
relevant practice of care for these two diseases in SSA,
analysing existing models. What are the factors of success?
What is the experience in practice? In the last part, we discuss
the possibilities of cross-fertilisation and improvement of
care for diabetes and HIV chronic care in SSA.
2. Methods
Weperformed our study in three phases. In the first phase, we
developed a conceptual “chronic dimension framework” that
allows the analysis of dimensions of chronic diseases relevant
for the management and organisation of care. The frame-
work was constructed through literature research and expert
consultation. We started from the three groups of actors
identified in the Innovative Care for Chronic Conditions
(ICCC) framework (health care organisation, community,
patient, and family) and a discussion among experts about
the characteristics of chronic conditions [16]. During a 3-day
workshop on health systems and chronic diseases with public
health scientists, these dimensions were elaborated [18].
Further reading deepened the elements of each dimension.
We then applied the framework to HIV/AIDS and diabetes,
to explore commonalities and diﬀerences.
The second phase comprised a literature review on care
delivery models for diabetes and HIV/AIDS, according to the
“decision support approach”, to develop a theory [19, 20].
Our search was guided by a number of questions.What mod-
els of care delivery and treatment of diabetes or HIV/AIDS
patients are used to reach large-scale coverage in SSA? What
are the channels of delivery, which kind of cadre is involved,
and how are the community and patients involved? We
reviewed twomajor databases (Pubmed and Google Scholar)
and the websites of relevant organisations (UNAIDS, WHO
and ministries of health of SSA countries). For HIV/AIDS,
the search terms were “HIV”, “AIDS”, “ART”, “health care
delivery”, “health care model”, “community health services”,
“decentralisation”, and “peer support”, in combination with
SSA. The search terms for DM were “diabetes”, “chronic
care”, “chronic disease management”, “chronic care model”,
“diabetes”, also in combination with “SSA” and specific
country names. We selected those articles that focused on the
description of delivery models, at conceptual or operational
level, and distilled the most important elements of the
existing models of care for both DM2 and HIV/AIDS.
In the third phase, we integrated the lessons from
the review into the framework. We analysed whether the
elements of existing care models for one disease would also
be relevant for the organisation of care and management of
the other one. Our recommendations were derived from a
consensus procedure with the authors as participants.
3. A Framework for Chronicity
The prevailing organisational design of health care is guided
by health professionals and determined by the biomedical
characteristics of a disease and medical care required. Is it
infectious? How frequently are medical check-ups desirable?
Which medical equipment should be available? However,
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Figure 1: The “Chronic Dimension Framework” to describe four
dimensions of chronic conditions.
chronic diseases result in a “biological disruption” for
patients, meaning that experiencing a chronic illness in
everyday life has enormous impact and necessitates a process
to incorporate such illness into life and identity, in terms
of cognitive processes and practical response [5]. In this
process, the involvement of family and environment is indis-
pensable. Recognizing this aspect means that optimal man-
agement of chronic diseases implies the adaptation of health
care organisation to take into account this patient and
environment perspective.
We designed a framework to analyse these four dimen-
sions of chronic diseases: the biomedical or “disease dimen-
sion”, the “health provider dimension”, the patient or “person
dimension” and the “environment dimension” (Figure 1).
This “Chronic Dimension Framework” can be used to
analyse the characteristics of any CLLC, to be able to identify
and clarify the needs for management and support taking
into account the disease-inherent characteristics and the
perspectives of actors involved. Although all dimensions are
related to each other and influence each other, the model
emphasises the views of each actor (patient, provider and
people in the environment) as key variables on their own, not
necessarily congruent with each other [21]. We will shortly
elaborate on them.
The disease dimension refers to the biomedical char-
acteristics, inherent to a disease. Examples are the onset
and the nature of progression-for instance the pace, level of
(un)certainty and interpatient variability, the risk for acute
fatal incidents, the physical changes, the risk of infection, and
mode of transmission [22]. The health provider dimension
entails the professional involvement with patients and their
disease. It raises questions such as: how complex is the
treatment; who can provide the treatment; how often is
patient contact necessary and what does it entail? What
is the provider’s point of view towards the patient and
his/her disease [21]? Are professionals of other disciplines
involved? The person dimension involves the experience of
patients themselves, their attitude towards their disease, their
way of coping, and their own role in disease management.
What is the role of self-management? What sort of life-
style adjustments are desirable and possible? How much do
patients suﬀer, physically and/or psychologically [23]? The
environment dimension relates to all actors (both personal
and institutional) interacting with patients and potentially
influencing their way of coping and their disease manage-
ment. This starts from the inner circle of family and house-
hold members, but extends to the consequences for work
and social life and to the role of stigma and how people feel
depicted in society. We applied this framework to compare
two increasingly prominent CLLCs in SSA, HIV/AIDS and
DM2 (Figure 2).
The disease dimension of DM2 and HIV/AIDS is that of
a slowly progressive disease, which in advanced stages leads
to increased morbidity aﬀecting multiple organ systems,
requiring diﬀerent professional expertise. The threat of
exposure to opportunistic infections such as meningitis and
tuberculosis, especially in SSA, contributes to uncertainty
about the progression of HIV/AIDS and a more pronounced
premature mortality for HIV/AIDS than for diabetes, espe-
cially in absence of ART. DM2 usually shows a gradual
progression, but entails a considerable risk of acute life-
threatening incidents such as hypo- and hyperglycaemia.
The most striking diﬀerence is the mode of transmission.
Diabetes is a noncommunicable disease, with a hereditary
component, triggered by life-style factors such as diet and
physical exercise. HIV/AIDS is infectious and is transmitted
through blood or venereal contact, its transmission being
associated with behaviour and lifestyle aspects that increase
the chance of infection. This diversity in risk factors and
transmission necessitates diﬀerent strategies at population
and individual level to control the spread of disease. The
risk of infection has a large impact on how the patient and
his environment interact, which we will discuss under these
dimensions.
From the health provider dimension, HIV/AIDS and
DM2 are managed quite diﬀerently. Nowadays, first line
treatment for HIV/AIDS is straightforward, comprising one
or two tablets a day, although patients side-eﬀects are still
an important barrier to treatment adherence [24]. Diabetes
treatment is more complicated, in terms of the choice of
treatment regimen, the combination of diet, tablets and
sometimes insulin and the adjustment of treatment to
variation in diet and exercise. Diabetes treatment can be
standardised into flowcharts, but these involve multiple steps
in decision-making and require some expertise and training
to handle them correctly [25]. The risk for an acute life-
threatening incident requires the availability of 24-hour
medical advice. These diﬀerences influence the feasibility
of decentralising treatment beyond primary care level. For
both DM2 and HIV/AIDS, the routine follow-up is periodic
and involves mainly monitoring of treatment and disease
progression. The crucial role of the professional health
provider is to detect and manage complications. The overall
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Figure 2: Comparing the chronicity dimensions of HIV AIDS and diabetes.
management of both groups of patients entails, besides the
medical tasks, a lot of counselling on how to live with the
disease.
The person dimension is highly aﬀected for both DM2
and HIV/AIDS, but in quite diﬀerent ways. DM2 requires
a lot of adjustments in the social spheres of life, such as
changing diet, maintaining a daily routine, and reducing
other cardiovascular risk factors such as smoking. People
living with HIV/AIDS (PLWHA) might face less intrusive
lifestyle adjustments, as they are merely related to avoiding
risk behaviour, but they generally do experience a large psy-
chological set-back from the diagnosis and its consequences.
Whereas diabetes is considered a disease you deserve no
blame for (and in some contexts even seen as a sign of
wealth), PLWHA are confronted with stigma and this often
leads to a great deal of psychological suﬀering. This stigma
has many origins, like the association of infection with sexual
contact in general, with particular behaviours considered
risky and stigmatised in themselves (homosexuality, drug
addiction, prostitution, or promiscuity), but also the lack
of information or the fear for a potentially lethal disease
[26]. This stigma, the change in attitude of people towards
PLHA, the ideas of PLHA themselves, and the real risk
of infecting others with a potentially lethal disease leads
to a lot of psychological distress and to an (implicit or
explicit) barrier between the person aﬀected and his/her
environment [27, 28]. This barrier hinders the search for and
finding of social and health service support [29], and the
result is that often necessary support is not found. Physical
suﬀering usually comes in advanced stages for both groups
of patients. The role of self-management in DM2 comprises
life-style adjustments discussed above, monitoring of glucose
levels and adaptation of medication, and recognition and
management of acute danger signs. The “technical” tasks
of self-management of HIV/AIDS are less complicated,
focusing on intake of oral medication, coping with side-
eﬀects, and knowing what to do in case of interruption,
and on the control of transmission. Whereas people with
diabetes observe an immediate influence of their behaviour
and subsequent glucose levels on their well-being, the signs
of not taking medication for PLWHA arise more gradually
but can be more ominous on the longer term, because of the
development of virus resistance.
The environment dimension for people with DM2 and
those with HIV/AIDS is greatly aﬀected, especially the imme-
diate circle of family life. Family members of DM2 patients
encounter the changes in meal patterns and composition
which usually aﬀect the whole family or require the cooking
of diﬀerent meals, but they also learn to recognize acute signs
of hypo-/hyperglycaemia and other complication symptoms.
HIV/AIDS aﬀects the sexual and aﬀective relationships
between partners, but possibly also with children. In families
of both patient groups, concerns about access to treatment
can have a large impact on the routine activities and other
needs in the family. In a similar way, social life and work can
be aﬀected by the disease. As discussed above, the enviro-
nment’s perception of HIV/AIDS and DM2 is very diﬀerent.
The stigma of HIV/AIDS makes it diﬃcult for PLWHA to
share with others, but it can bring patients closer to each
other [30]. The still dominant perception of diabetes as a
disease for the rich leads to a more individualised experience.
Our framework reveals that HIV/AIDS and DM2, at
first sight very diﬀerent diseases, also share some com-
parable characteristics in the health provider, person, and
environment dimensions. The health provider dimension is
crucial for the organisation of care, for example, the choice
of the most appropriate platforms for delivering medical
care, the need for a permanent service within reach, the
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involvement of other professionals, the possibilities for self-
management, and the role of families. The person and
environment dimensions determine the kind of adjustments,
feasibility, and challenges when empowering patients and
involving the family and others in helping the patient to
manage his/her disease. Although the content of life-style
adjustment and impact might be diﬀerent, the experienced
intensity of the disease, the processes involved in motivation,
empowerment, and behavioural changes are similar. The
comparison illustrates that it is useful to think about
management of diabetes and HIV/AIDS in health systems
in tandem, to compare care delivery platforms, strategies for
self-management, and involvement of the environment. In
the following section, we will look at the practice of care for
both diseases, to see which lessons can be learnt.
4. Present Models of Care for Diabetes and
HIV AIDS for SSA
For both diseases, there is not one care model, such as
the “DOTS approach”, which has been universally endorsed
by the WHO for tackling tuberculosis [31]. Instead, many
organisations have experimented with an approach of their
own, leading to various delivery models. Some of them have
been endorsed at national level and subsequently scaled up.
Many early publications about ART in SSA address the
barriers to long-term quality care, such as costs, interrupted
drug supplies, the lack of referral system, weak clinical
management with insuﬃcient attention for retention in care,
and provider-patient interaction and poor social support
[32]. Some early care projects for PLHA were modelled upon
the DOTS strategy, but the approach was doubted to be
useful and appropriate for a Chronic Life-Long Condition
such as HIV/AIDS [33–35]. The Millennium Development
Declaration turned the HIV/AIDS epidemic into a matter
of international political urgency and increased resources
facilitated programmes to deliver treatment and care to
PLWHA [36]. Access to ART in low- and middle income
countries increased from 400 000 in 2003 to 6.65 million in
2010, or 47% coverage of people eligible for treatment [37].
Manyministries, international development actors, and local
organisations experimented with delivery models, while also
trying to expand coverage at the same time.
There are only a handful of publications on small-scale
experiments to provide care for DM2 in SSA. The 2011 NCD
summit resulted in five priorities for national strategies,
but the care component has so far received only minimal
attention, mainly mentioning the need for a primary care
based delivery and access to essential medicine [38]. The
reality in SSA is that care for people with diabetes is of low
quality. Routine practice is that care in the public sector is
mostly provided at secondary level and that the gap at the
first line is filled by a variety of private providers.
4.1. HIV/AIDS Care. The papers we retrieved from our
review included programmatic guidelines of the World
Health Organisation (WHO) and of Ministries of Health
of SSA countries; papers describing individual (single or
multi-country) studies with various models of care; system-
atic reviews; and more general articles identifying barriers
to care and health system links. We found papers at pilot
project level from Tanzania, Malawi, South Africa, Zambia,
andMalawi [39–44]. The delivery approaches described were
mostly centred at primary care level with a strong commu-
nity component sometimes using additional tools, such as
mobile phones. From reviewing these papers, we distilled
three major issues, which we elaborate further: (1) rapid
scale-up approaches through the public health approach;
(2) community and peer support; and (3) strengthening the
health services in which care is embedded.
Rapid Scale-Up Strategy through the Public Health Approach.
To rapidly scale-up ART in SSA, where health systems are
overall weak and have huge shortages of health workforce,
it was soon realised that the care model from Europe and
the United States with an individualised medical approach,
hospital-based clinics, specialist consultation, and regular
follow-up of clinical parameters was not possible. To deal
with these challenges, WHO proposed a “public health
approach” which prioritised large-scale access to treatment
over maximising individual treatment. The main principles
of the public health approach are simplification of treatment
protocols and clinical monitoring; decentralisation of ART
care delivery to the local health centre and community
level; and task shifting and involvement of community and
PLWHA in program design, management, and care [45].
Diagnostic and treatment protocols were rationalised
and standardised, by reducing the number of laboratory tests
and introducing Fixed Dose Combinations (FDC) tablets.
Core responsibilities and core tasks were delegated to lower
cadre health workers [40, 46, 47]. For instance, nurses were
trained and became responsible to initiate and follow up
patients on first line ART [40, 48]. New health cadres were
created to diminish the workload in health facilities and
to reinforce the link with the community, for instance lay
providers who could provide specific ART care delivery
functions like adherence support, defaulter tracing, educa-
tion, and counselling [49]. The results of these approaches
indicate that they can successfully improve access to ART
with good quality. Pilot projects in Tanzania, Malawi, South
Africa, Zambia, and Mozambique show similar or improved
treatment outcomes for PLWHA receiving decentralised care
compared to hospital-based care [44, 46, 50–54].
Community and Peer Support. In many HIV/AIDS pro-
grammes, there is a large role for the community and for
patient groups. These community and peer supports usually
take up tasks like psychosocial or adherence support and
defaulter tracing [55, 56]. The main results published relate
to improved retention of patients in care, when such persons
are involved in care delivery [57–61]. Community and
patient involvement can contribute to their empowerment.
To ensure lifelong adherence to treatment, it is important
to involve PLWHA in their daily care and to demedicalise
care where possible, for instance by separating medical
consultation from drug refills. Some pilot projects show the
feasibility to involve the community and PLWHA also in
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medical tasks such as ART provision in the community in
Mozambique and Kenya [56, 62, 63]. The main pillars of
these projects are the empowerment of the PLWHA, peer
support, and information sharing.
Strengthening Health Services and Health Systems. Condi-
tions for successful decentralisation to primary care level are
that such facilities function well, that a minimum of required
support services are in place (for instance referral laboratory,
trained human resources, continuous drug supply) and
that other essential functions are not endangered by the
additional tasks of ART. This led to the realisation that
decentralisation and scaling-up of ART also necessitated
investment in workforce and in the general infrastructure
[64–66]. In two countries with successful scaling-up, Malawi
and Ethiopia, HIV earmarked donor funding was used
to strengthen the health system. The expansion of health
workforce contributed to an overall increase in functional
health facilities and an improvement of utilization rate and
health outcomes was noticed [67].
4.2. Diabetes Care. There are very few publications about
delivery of diabetes care in SSA, most of them describ-
ing local-level initiatives, without explicit reference to a
framework. We also included papers which elaborate models
often referred to as examples for SSA [11]. The papers
reviewed included descriptions of models for care for chronic
diseases and their meta-evaluations; specific models of care
for diabetes; overviews of diabetes care in SSA or partic-
ular countries; individual studies on delivery of care. The
publications about diabetes care in SSA came from South
Africa [68], Ethiopia [69, 70], DR Congo [71], Tanzania, and
Cameroon [72, 73].
The most known model is the Chronic Care Model
(CCM), which has been implemented and evaluated in
many high income countries [74]. It proposes a redesign
of care organisation, to include self-management; clinical
guidelines; an information system allowing for stratification
according to risk profiles and subsequent follow-up; reor-
ganising care delivery focusing on teamwork and continuous
care; creating community linkages and mobilising resources
[75]. Meta-analyses indicate that implementation of the
CCM improves quality of care and clinical outcomes, but
there is no clarity about which elements are essential or to
what extent [76, 77]. There have been initial steps to intro-
duce the CCM in Uganda and in Ethiopia, but these have
not yet been evaluated [2, 78]. Although not explicit, some
chronic disease projects in SSA bear features of the CCM,
particularly clinical guidelines, education programmes, and
continuous care [72]. TheWHO Innovative Care for Chronic
Conditions (ICCC) Framework is an adaptation of the CCM,
which expands to the policy environment and puts more
emphasis on the role of the community, to be applicable
also in LIC [16]. The ICCC framework has only incidentally
been used in practice and has, as far as we know, not been
implemented at operational level in SSA [79]. In 2011, the
WHO published a Package of Essential Noncommunicable
(PEN) Disease Interventions for primary health care in low
resource settings, which does not entail a real “model” for
delivery, but provides a number of tools to organise care for
a noncommunicable disease [80].
From the experiences with models in HIC and from
the publications about projects in SSA, we have identified
two important issues: (1) decentralisation and task-shifting;
and (2) involvement of patient groups and self-management
strategies.
Decentralisation and Task-Shifting. Most of the projects in
SSA started from a hospital and were then extended to the
local health centre level, executed by nurses, and supervised
by mobile (teams of) specialists. Training, supervision
and diagnostic and treatment protocols were developed to
support health centre staﬀ [68–72]. Those projects which
reported on results, mention that people remain in follow-
up and that clinical outcomes are comparable with specialist
care. Approximately 80% of all patients in the district could
be treated at primary care level [68, 70]. Similar to the ART
approach, decentralisation processes entailed task-shifting to
lower cadre, diﬀerentiation between routine and complicated
cases, training of staﬀ and education to patients and families,
aﬀordable drugs supply, and sometimes additional social care
for the most vulnerable groups.
Involvement of Patient Peer Groups and Self-Management
Strategies. Self-management is a CCM component, but has
also been developed and implemented as a strategy in itself,
in order to support patients with chronic diseases to develop
knowledge and skills necessary for self-care [81, 82]. Self-
management strategies can improve clinical outcomes and
patient empowerment [83–86]. Self-management and peer
support are reciprocal dimensions that are often combined
in support programmes. Peer patient groups learn about how
to cope with and self-manage their disease and peer groups
develop mechanisms to support each other, materially,
mentally, and socially [83, 87].
For diabetes, self-management has been translated into
an education programme focusing on problem-solving,
decision-making, and confidence-building of patients,
addressing diabetes-specific dimensions [88, 89]. Peer
support for diabetes has been described in LIC outside
of SSA, such as Cambodia [90]. In SSA, there is a growth
of national and local diabetes patient associations, for
instance to organise access to treatment or to stimulate peer
support and there is increased attention for their potential
[5, 73, 91, 92].
5. Lessons to Improve Chronic Care
In the former section, we distilled lessons from the present
models of care for HIV/AIDS and DM2, relevant for SSA.
An inclusion of these lessons into our chronic dimension
framework shows the potential for cross-fertilisation be-
tween models (Figure 3). In order to cope with chronic care
for PLWHA and people with diabetes, health systems in SSA
need to move to simplification of treatment and encour-
agement of self-management.
Although there are diﬀerences in complexity of treat-
ment, practice shows that decentralisation and task-shifting
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Figure 3: Potential cross-fertilisation of present care models of HIV/AIDS and diabetes, taken into account the chronicity dimensions.
is possible for both DM2 and HIV/AIDS. The public health
approach, focusing on rapid scale up and simplification and
standardisation of treatment, could be much more exploited
to improve access to diabetes treatment. The treatment
guidelines for SSA of the World Diabetes Federation are a
useful document in this sense, but they are not very widely
distributed and used [25]. The FDC tablet meant huge
progress in the simplification of ART, making it much easier
for PLHA to adhere to treatment. There are also gains to
be made in the access to and rational use of blood glucose
testing materials, insulin, and oral antidiabetic medication
in LIC [93, 94]. A universal minimal monitoring package
would greatly facilitate simplification and comparison [95].
However, the large and growing number of patients living
with one or both diseases makes it urgent to transfer more
responsibilities to patients themselves [5]. Argumentation
goes beyond rationalisation of resources and should be
part of strategies to empower patients to cope with their
CLLC [5]. HIV/AIDS models have a lot of experience with
activating community and peer support for patients, but the
concept of self-management has been hardly discussed in
the scope of individual care. The experiments that involve
PLWHA in the delivery of ART are promising and should
be further evaluated. The patient associations for HIV/AIDS
and diabetes have large potential, but their objectives and
strategies are often not yet well-developed. Both groups
could learn a lot from self-management programmes devel-
oped in HIC.
The last lessons from our analysis relate to health system
organisation. The HIV/AIDS models illustrate that decen-
tralisation to primary care level cannot be realised without
strengthening the primary care services themselves. This
means for instance investment in laboratory analysis, patient
centred care, and counselling services and follow-up. This
could benefit the primary care for other chronic diseases.
Some of the projects discussed expanded their care model
to other chronic conditions, for instance from diabetes
towards also hypertension and asthma patients [68, 72].
A more in-depth evaluation of such an integrated project
which also includes HIV/AIDS patients has been described in
Cambodia, which showed that “staﬀ could eﬀectively assume
a multidisciplinary role and that skills to manage patients
who need to start lifelong treatment were relevant to and
eﬀective for both HIV/AIDS and diabetic care”, for instance
a patient-centred approach and adherence support [96].
The bundled care for diabetes and other chronic diseases
is particularly relevant for DM2 and HIV/AIDS, since both
diseases and their combination are increasingly important
in SSA, because ART-induced diabetes leads to increased
comorbidity, and because the rising incidence of diabetes
in SSA results also in more patients who happen to have
both diseases. However, comorbidity of chronic diseases is
a quantitatively important phenomenon, in general practice
among elderly people, but even more prominent and at a
younger age among PLHA [17, 97]. Therefore, the lessons
from our paper are also relevant for other CLLC, such as
hypertension and chronic lung disease.
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